Lack of significant toxicity after mirtazapine overdose: A five-year review of cases admitted to a regional toxicology unit
ABSTRACT Mirtazapine is a comparatively new antidepressant that selectively blocks central alpha2-adrenergic autoreceptors and postsynaptic 5-HT2 and 5-HT3 receptors, causing reduced neuronal norepinephrine and serotonin reuptake. The prevalence of mirtazapine prescribing has steadily risen; however, comparatively little information is available regarding the clinical features associated with mirtazapine overdose.
To characterize the toxic features that result from mirtazapine overdose.
We performed a retrospective case analysis of patients admitted to the Toxicology Unit of the Royal Infirmary of Edinburgh between January 2000 and December 2004 after stated mirtazapine overdose. Casenotes were examined for clinical, laboratory, and electrocardiographic safety data.
There were 117 mirtazapine cases where the median (interquartile range) stated dose ingested was 450 mg (240-785 mg). Conscious level was reduced in 27.2% of patients and there was a higher incidence of tachycardia (30.4%) than predicted from normal reference range values (p < 0.001). There was no evidence of any other significant clinical, laboratory, or electrocardiographic abnormality.
Severe toxic features could be attributed to other co-ingested drugs or alcohol. The adverse clinical effects attributable to mirtazapine overdose appeared mild and predictable. Mirtazapine overdose appears to be associated with fewer features of severe toxicity than previously reported for other antidepressants.
Full-textDOI: · Available from: W. Stephen Waring, Aug 18, 2015
Click to see the full-text of:
Article: Lack of significant toxicity after mirtazapine overdose: A five-year review of cases admitted to a regional toxicology unit
- SourceAvailable from: Yesim Tuncok
[Show abstract] [Hide abstract]
- "Adenosine causes hypotension by inducing the A 2 receptors (Lerman and Belardinelli, 1991). Sinus tachycardia is a common anticholinergic effect in humans after tricyclic antidepressant poisoning (Whyte et al., 2003; Waring et al., 2007; Klasco, 2009). In our study, amitriptyline infusion did not cause any significant change in HR. "
ABSTRACT: We planned this study in order to investigate the effects of theophylline on cardiovascular parameters in an anaesthetized rat model of amitriptyline toxicity. In the preliminary study, we tested theophylline as 1 mg/kg of bolus, followed by a 0.5-mg/kg infusion. Toxicity was induced by the infusion of 0.94 mg/kg/min of amitriptyline up to the point of a 40-45% inhibition of mean arterial pressure (MAP). The rats were randomized to two groups: a group of 5% dextrose bolus followed by 5% dextrose infusion, and another group with theophylline bolus followed by infusion. Amitriptyline caused a significant decrease in MAP and prolongation in QRS; however, it did not alter heart rate (HR). When compared to the dextrose group, theophylline administration increased MAP, shortened prolonged QRS duration, and increased HR (P < 0.05, respectively). There was no statistically significant difference in the results of arterial blood-gas analyses among the groups (P > 0.05). Bolus doses followed by a continuous infusion of theophylline were found to be effective in reversing the hypotension and QRS prolongation seen in amitriptyline toxicity. One of the possible explanations of this beneficial effect is nonselective adenosine antagonism of theophylline. Further studies are needed to reveal the exact mechanism of the observed effect.Drug and Chemical Toxicology 10/2010; 34(1):53-60. DOI:10.3109/01480545.2010.495947 · 1.10 Impact Factor
[Show abstract] [Hide abstract]
- "It correctly predicts those drugs that are unable to precipitate ST, such as those TCAs that are insufficiently potent as SRIs to cause serotonergic side-effects or serotonergic interactions with MAOIs (Gillman, 2006a). A similar lack of serotonergic effects (at either therapeutic doses or after overdose, or on interaction with MAOIs) is found with trazodone , nefazodone, mianserin and mirtazapine (Biswas et al., 2003; Gillman, 2003; 2004; Isbister and Hackett, 2003; Isbister and Whyte, 2003; LoVecchio et al., 2008; Schaper et al., 2002; Waring et al., 2007). A clear understanding of these interactions is heuristically valuable in revealing the mechanism of action, and potency, of many psychotropic drugs and allows confident predictions about them to be made (for details and discussion, see Gillman, 2006a): in this instance the prediction, now confirmed, that MB is an MAOI. "
ABSTRACT: Methylene blue has only recently been noted to cause severe central nervous system toxicity. Methylene blue is used for various conditions, including, intravenously, in methemoglobinemia, vasoplegia and as an aid to parathyroidectomy (at doses of 1-7.5 mg kg(-1)). This review of the current evidence concludes that 13 of 14 of the reported cases of CNS toxicity were serotonin toxicity that met the Hunter Serotonin Toxicity Criteria. That has important preventative and treatment implications. Serotonin toxicity is precipitated by the monoamine oxidase inhibitor (MAOI) property of methylene blue interacting with serotonin reuptake inhibitors. Serotonin toxicity is reviewed, using the lessons inherent in the methylene blue story and experience, to illustrate how the mechanisms and potency of serotonergic drugs interact to determine severity. Recent human data showed that an intravenous dose of only 0.75 mg kg(-1) of methylene blue produced a peak plasma concentration of 500 ng ml(-1) (1.6 µM), indicating that the concentration in the central nervous system reaches a level that inhibits monoamine oxidase A. That is consonant with the actual occurrence of severe serotonin toxicity in humans at the dose of only 1 mg kg(-1). It seems that all proposed uses of methylene blue entail levels that block monoamine oxidase, so cessation of serotonin reuptake inhibitors should be very carefully considered before using methylene blue.Journal of Psychopharmacology 02/2010; 25(3):429-36. DOI:10.1177/0269881109359098 · 2.81 Impact Factor
Article: MirtazapineCNS Drugs 01/2009; 23(5). DOI:10.2165/00023210-200923050-00006 · 4.38 Impact Factor